



**UCL/UCLH Joint Research Office**

**Office Location:**

1<sup>st</sup> Floor Maple House  
149 Tottenham Court Road  
London W1T 7DN

**Postal Address:**

UCL,  
Gower Street  
London WC1E 6BT

Email: [ctimps@ucl.ac.uk](mailto:ctimps@ucl.ac.uk) Tel No. 020 3447 5557 Fax No. 020 3447 9937

Web-sites: [www.uclh.nhs.uk](http://www.uclh.nhs.uk); [www.ucl.ac.uk/jro](http://www.ucl.ac.uk/jro)

01/11/2017

Dr Martin Forster  
Department of Oncology  
250 Euston Road  
London NW1 2PG

Dear Dr Forster,

**Trial Title:** A randomised phase II study evaluating the safety and anti-tumour activity of the combination of avelumab and cetuximab relative to avelumab monotherapy in recurrent/metastatic head and neck squamous cell cancer

**Short Title:** EACH

**Funder:** Merck Serono

**Sponsor R&D ID number:** 17/0560

I confirm that University College London (UCL) will act as Sponsor for the above trial.

As Sponsor, UCL will undertake to ensure that the above trial is conducted in accordance with the Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended) and the Research Governance Framework (Second Edition April 2005). The **Cancer Research UK and UCL Cancer Trials Centre** has agreed to undertake delegated sponsor duties and will co-ordinate the above study.

As Chief Investigator, you must ensure that the above trial will not commence until all applicable approvals have been obtained and in agreement with the Trials unit.

Yours sincerely,



Gemma Jones  
**Clinical Trials Operations Manager**

cc. Nicky Gower, CR UK and UCL Cancer Trials Centre

